Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, susceptibility to which is associated with genetic and environmental factors. RA is treated with disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate, d-penicillamine, sulfasalazine, gold salts, anti-malarial drugs, and biological agents. One such DMARD is bucillamine (Buc) [(2R)-2-(2-methyl-2-sulfanylpropanoylamino)-3-sulfanylpropanoic acid], a thiol compound like d-penicillamine.
1,2 Buc has been used for the treatment of RA in Japan for 26 years. It was known that drug-induced proteinuria can occur in RA patients treated with d-penicillamine or gold salts. 4, 5 Bucinduced proteinuria (BI-Pro) because of membranous nephropathy is also reported; the prevalence of BI-Pro was reported to be 5.3%. 6, 7 BI-Pro cases developed proteinuria without renal dysfunction on Buc treatment, but this disappeared after discontinuing the drug. However, the mechanism responsible remains unclear. It was suggested that tubular basement membrane and renal tubular epithelial antigens released from renal tubules damaged by thiol compounds invoke the generation of autoantibodies against them and induce membranous nephropathy. 8 If biomarkers for predicting BI-Pro were exploited, Buc could be a more useful DMARD.
Certain human leukocyte antigen (HLA) alleles are known to be associated with RA in most ethnic groups, 9 especially HLA-DRB1 12 or methotrexate-induced interstitial lung disease and A*31:01. 13 These observations imply that HLA plays a substantial role in drug-induced hypersensitivity reactions. The molecular mechanisms underlying drug hypersensitivity associated with certain HLA alleles remain unclear. The product of the interaction of HLA molecules with drugs may directly activate T cells.
14 Alternatively, drugs or their metabolites may act as haptens binding to peptides already loaded on the HLA molecules. Furthermore, a drug-modified HLA-peptide repertoire may trigger drug hypersensitivity. 15 Several studies have focused on proteinuria induced by thiol compounds in RA and reported strong associations with HLA class II allele, DR3, in people of European descent. 16, 17 Here, we investigated HLA class II associations with proteinuria induced by the thiol compound, Buc, in Japanese RA patients.
Materials and Methods
Patients and controls. A total of 25 RA patients with episodes of BI-Pro and 460 control RA patients without any episodes of BI-Pro under Buc treatment were recruited at Sagamihara Hospital, Tama Medical Center, Nagasaki Medical Center, and Yokohama Minami Kyosai Hospital. BI-Pro was defined as developed proteinuria during Buc treatment that disappeared after discontinuing the drug. The proteinuria was diagnosed by spot qualitative urinalysis results. No BI-Pro case was histologically confirmed. No BI-Pro case has been complicated with other renal disorders. No BI-Pro case was treated with other DMARDs than Buc, while suffering from BI-Pro. All patients with RA were native Japanese and fulfilled the 1988 American College of Rheumatology criteria for RA. 18 This study was reviewed and approved by the research ethics committees of each participating institute, namely Sagamihara Hospital, Nagasaki Medical Center, Yokohama Minami Kyosai Hospital, Tama Medical Center, and University of Tsukuba. Written informed consent was obtained from all study participants. This study was conducted in accordance with the principles expressed in the Declaration of Helsinki.
genotyping. Genotyping of HLA class II alleles was performed by polymerase chain reaction with sequence-specific oligonucleotide probes using WAKFlow HLA typing kits (Wakunaga, Hiroshima, Japan) and the Bio-Plex 200 system (Bio-Rad, Hercules, CA). DRB1-DQB1 haplotypes were elucidated by direct counting. Some of the RA patients were also included in other studies that reported on susceptibility effects for interstitial lung disease. 13, 19 statistical analysis. Differences in RA characteristics and allele or haplotype carrier frequencies were analyzed by Fisher's exact test using 2 × 2 contingency tables or MannWhitney's U test. Alleles with more than 1% of the frequency in RA were tested. Adjustment for multiple comparisons was performed using the Bonferroni method. Corrected P (Pc) values were calculated by multiplying the P value by the number of alleles tested. The specificity, the sensitivity, the positive likelihood ratio, and the negative likelihood ratio were calculated under the dominant model. The number of persons who would need to be screened to prevent one incident of BI-Pro was also estimated from the reported prevalence of BI-Pro. Table 1 . Duration of Buc treatment in RA patients with episodes of BI-Pro was shorter than in the RA patients without any episodes of BI-Pro. There were no significant differences in terms of mean age, percentage of males, disease duration, Steinbrocker stage, association of secondary Sjögren's syndrome, rheumatoid factor, anti-citrullinated peptide antibody, dose of Buc, anti-Ro/SS-A antibody, anti-La/ SS-B antibody, or history of methotrexate (MTX) or biologic DMARDs treatment between RA patients with episodes of BI-Pro and RA patients without any episodes of BI-Pro under Buc treatment.
Association of hlA class II allele carrier frequencies with bI-Pro. We tested whether the carrier frequencies of any HLA alleles were increased in RA patients with BI-Pro. A significant association was found for HLA-DRB1*08:02 
discussion
Several studies have shown that HLA polymorphism contributes to susceptibility to adverse drug reactions. 4, 5, 20 To the best of our knowledge, the present report is the first to show an association of DRB1*08:02 with BI-Pro in Japanese RA patients. DRB1*08:02 would be a useful clinical marker to prevent BI-Pro. Its prevention has crucial significance for the safety of clinical practice in RA. Thus, these findings provide useful information for promoting personalized medicine for RA.
The RA patients with secondary Sjögren's syndrome or anti-Ro/SS-A antibodies are more prone to develop adverse effects when treated with DMARDs. [21] [22] [23] The HLA-DR3 allele is strongly associated with the presence of anti-Ro/ SS-A antibodies in patients of European descent. 24 These data explain the strong association of HLA-DR3 with druginduced proteinuria in European RA patients. 16, 17 A recent study has shown that the frequency of the DRB1*08:03 allele is significantly higher in Japanese RA patients with anti-Ro/ SS-A antibodies than in those without, and that the frequency of DRB1*08:02 is also higher, but not statistically significantly so. 25 However, the frequency of DRB1*08:03 was not higher in RA patients with BI-Pro, but DRB1*08:02 was (Tables 2). In our study, 4 of 25 RA patients with BI-Pro were associated with secondary Sjögren's syndrome and the frequency was higher than that in RA patients without BI-Pro, though the difference did not reach significance (Table 1) . In addition, 4 of 25 RA patients with BI-Pro were positive for antiRo/SS-A antibodies and the frequency was similar to that in RA patients without episode of BI-Pro (Table 1) . Therefore, anti-Ro/SS-A antibodies in RA patients would not be a marker for BI-Pro in Japanese patients. This preliminary study showed a highly significant association of DRB1*08:02 with BI-Pro, although the sample size of the study is small and the selection bias could not be avoided in retrospective case-control studies. Therefore, the association needs confirmation in future largescale prospective studies. We also cannot rule out the possibility that other genes causing these reactions might reside in the HLA region in linkage disequilibrium with the DRB1*08:02-DQB1*04:02 haplotype. This possibility could be addressed by re-sequencing the entire HLA region of the haplotype.
conclusion
To our knowledge, this is the first identification of an association of the DRB1*08:02 allele with susceptibility to BI-Pro Abbreviations: HLA, human leukocyte antigen; RA, rheumatoid arthritis; BI-Pro, bucillamine-induced proteinuria; BI-Pro(+), RA with BI-Pro; BI-Pro(−), RA without BI-Pro; OR, odds ratio; CI, confidence interval;
Pc, corrected P value. Allele carrier frequencies are shown in parenthesis (%).
in Japanese RA patients. Our findings support a role for DRB1*08:02 in BI-Pro pathogenesis and its potential clinical usefulness as a biomarker.
